ArticleCureus2025
Amoxicillin-Induced Hemolytic Uremic Syndrome and Kidney Injury: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Amoxicillin (AMX) is a commonly used antibiotic for treating infections and as a prophylactic antimicrobial agent, appreciated for its efficacy and favorable pharmacokinetics. Drug-induced acute kidney injury (AKI) significantly increases morbidity and mortality. Hemolytic uremic syndrome (HUS) is classified under thrombotic microangiopathies (TMAs), which are characterized by hemolysis, low platelet counts, thrombus formation in small vessels, and end-organ damage. While AMX-induced HUS has not been previously reported, AMX can cause AKI through mechanisms such as acute interstitial nephritis and AMX-induced crystal nephropathy (AICN), with AICN being more common. We present the case of a 56-year-old woman who developed AMX-induced HUS and AKI following AMX administration for a tooth infection. A kidney biopsy revealed distinctive glomerular damage, consistent with acute tubular injury and focal segmental glomerulonephritis. The diagnosis of drug-induced kidney injury with concurrent TMA was confirmed. AMX was discontinued, and the patient received plasmapheresis and hemodialysis. Typically, renal impairment is reversible once the offending agent is withdrawn. Physicians should be aware of the potential for AMX-induced HUS. Comprehensive medical history, physical examination, and prompt therapeutic intervention are crucial for effective treatment and improved patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.